Patient-Specific Models of Treatment Effects Explain Heterogeneity in Tuberculosis

Patient-Specific Models of Treatment Effects Explain Heterogeneity in Tuberculosis

Publication date: Nov 15, 2024

Tuberculosis (TB) is a major global health challenge, and is compounded by co-morbidities such as HIV, diabetes, and anemia, which complicate treatment outcomes and contribute to heterogeneous patient responses. Traditional models of TB often overlook this heterogeneity by focusing on broad, pre-defined patient groups, thereby missing the nuanced effects of individual patient contexts. We propose moving beyond coarse subgroup analyses by using contextualized modeling, a multi-task learning approach that encodes patient context into personalized models of treatment effects, revealing patient-specific treatment benefits. Applied to the TB Portals dataset with multi-modal measurements for over 3,000 TB patients, our model reveals structured interactions between co-morbidities, treatments, and patient outcomes, identifying anemia, age of onset, and HIV as influential for treatment efficacy. By enhancing predictive accuracy in heterogeneous populations and providing patient-specific insights, contextualized models promise to enable new approaches to personalized treatment.

PDF

Concepts Keywords
Biomed Al
July Context
Pies Contextualized
S1532046422001022 Doi
Tuberculosis Heterogeneity
Heterogeneous
Https
Lengerich
Models
Outcomes
Patient
Specific
Treatment
Tuberculosis
Url

Semantics

Type Source Name
disease MESH Tuberculosis
pathway KEGG Tuberculosis
disease MESH morbidities
disease MESH anemia
drug DRUGBANK Sulpiride
drug DRUGBANK Etodolac
drug DRUGBANK Coenzyme M
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH death
drug DRUGBANK Spinosad
disease MESH Hepatitis
disease MESH drug interactions
disease MESH tic
drug DRUGBANK Trestolone
drug DRUGBANK L-Valine
disease MESH unemployment
drug DRUGBANK Clarithromycin
drug DRUGBANK Pyrazinamide
drug DRUGBANK Kanamycin
drug DRUGBANK Terizidone
drug DRUGBANK Aminosalicylic Acid
drug DRUGBANK Streptomycin
pathway KEGG Drug metabolism
disease MESH Iron deficiency anemia
disease MESH cancer
disease MESH Lung Cancers
disease MESH COVID 19
disease MESH Lung Disease

Download Document

Leave a Comment

Your email address will not be published. Required fields are marked *